For Hege Hansen and Stine Andreasen, the decision to build a medical technology company came from years spent working directly with women in clinical settings.
Hansen is a midwife with more than 20 years of clinical experience in obstetric departments. Andreasen is a specialist in gynaecology and obstetrics, holds a PhD in Obstetrics and has more than 15 years of clinical experience. Together, they founded Norwegian medtech company Induvita in 2022.
Their starting point was straightforward. After years of working in gynaecology and obstetrics, the two healthcare professionals believed that some of the equipment used in women’s healthcare had not been designed sufficiently around the needs of patients or clinicians.
Their first product idea emerged during a night shift at their local hospital. That experience eventually developed into a company focused on medical devices and training tools for gynaecology and obstetrics.
Today, Induvita is preparing to bring its redesigned Vega vaginal speculum to the European market, while continuing development of its Iola induction catheter.
From the Clinic to the Boardroom
The founders did not come to medtech from traditional technology or investment backgrounds. They came from clinical practice.
That experience remains central to Induvita’s product development. The company says its devices are developed through evidence-based innovation and functional design, with the aim of improving patient experience while supporting healthcare professionals during examinations and procedures.
The company’s first products were Runa and Ayla, vaginal simulators designed for students and healthcare professionals to practise gynaecological examinations and obstetric procedures.
According to Induvita, the simulators are now sold globally and generated more than NOK 1 million in revenue during their first year on the market.
But the founders had a bigger opportunity in mind.
Redesigning the Speculum
The traditional vaginal speculum has changed relatively little over decades. Induvita’s answer is Vega, a single-use speculum designed specifically for gynaecological and obstetric examinations.
Induvita describes Vega as non-mechanical, ergonomic and pinch-free, with elastic sidewalls designed to support visibility during examinations. It is also designed to be quiet and at room temperature, addressing some of the discomfort associated with traditional instruments.
The company plans to launch Vega in autumn 2026.
The product is part of a wider effort by Hansen and Andreasen to rethink equipment used in women’s healthcare rather than simply accept established designs.
Their second major medical device is Iola, an induction catheter being developed for use in labour induction. Hansen and Andreasen are named as the inventors behind the patented technology, which was developed while they were working at Nordland Hospital in Bodø. Induvita holds a licence to commercialise the invention.
A New Funding Milestone
That work has attracted new investment.
In September 2026, Induvita raised NOK 7.5 million, approximately US$800,000, in a funding round involving new investors Magisk Potet AS and Fan Wing AS alongside existing shareholders.
The latest funding brings the company’s total investor funding since its founding to approximately NOK 17.9 million. The new capital will support the commercialisation of Vega and continued development of Iola.
For a company founded by two healthcare professionals, it represents an important transition from developing products based on clinical experience to bringing those products into wider use.
Induvita was also named Health Start-up of the Year at Norway’s Health Technology Conference in 2025.
Building a Business Around Clinical Experience
Hansen and Andreasen’s story is notable because their entrepreneurial journey began with a problem they encountered in their professional lives.
Hansen now serves as Chief Executive Officer, while Andreasen is Chief Medical Officer and a board member. Their roles reflect the two sides of the company: building and commercialising the business while retaining a strong clinical foundation.
The pair are now taking Induvita into its next stage, with Vega moving towards market launch and Iola continuing through development.
Their approach is centred on a simple principle: medical equipment should work for both the healthcare professional using it and the woman receiving the care.
For Hansen and Andreasen, that principle has become the foundation of a business designed to change how some of the most routine procedures in women’s healthcare are performed.
